Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
May 3, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has...
-
Apr 5, 2017Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment and other Neurological Conditions
Tel-Aviv, Israel, April5, 2017 – Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinicalstage pharmaceutical company specializing in the development of cannabinoid-based drugs,...
-
Apr 3, 2017
Tel-Aviv, Israel, April 3, 2017 – Therapix Biosciences Ltd. (NASDAQ; TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs,...
-
Mar 27, 20172,000,000 American Depository Shares Priced at $6.00 per ADS
Tel-Aviv, Israel, March 27, 2017 – Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...
-
Mar 22, 2017
Tel Aviv, Israel, March 22, 2017 – Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...